The Role of Ivermectin in the Management of Covid 19 [SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)]
Abstract
Protocols:
• The Chairman of this occasion.
• The President OSN, Dr. Bade Ogundipe
• Members of the Executive of OSN
• My colleagues/Seniors in the OSN
• Members of the Theodor Okechukwu Family
• Other invited Guests
• Ladies and Gentlemen.
I would like to thank the President and Council of the Ophthalmological Society of Nigeria (OSN) and indeed the Local organizing committee of the Ophthalmological Society of Nigeria Ilorin 2021 meeting, for inviting me to give this year’s Okechukwu memorial lecture. I was indeed a bit baffled when Professor Dupe Popoola called me up on the phone to discuss this. I reminded her that, in the year 2017, not too long ago, I had been invited to deliver the President’s lecture at the OSN which held in Kaduna. But she pointed out, rather correctly, that the tone and intent of the Okechukwu lecture differed from that of the President’s lecture. I am not sure if any other person in the annals of our society has had the privilege of delivering both lectures. If indeed I am the first to do so, as I suspect, I must ask myself why I have been so humbled! It is indeed a spectacular honour to have been given this double assignment, particularly when I consider the greats who are my seniors, such as Professors Olurin, Majekodunmi, Abiose, Oshuntokun and Hannah Faal, to mention but a few. My special thanks to the society know no bounds... (Click of the Download for the Complete presentation)
References
Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, Babalola OE, Alexander ND, Nuhu I, Evans J, Ibrahim UF, et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993 Jan 16;341(8838):130-134. doi: 10.1016/0140-6736( 93) 90002-x. PMID:
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.anti viral. 20 20.104787. Epub 2020 Apr 3. PMID: 32251768; PMCID:
Camprubí D, Almuedo-Riera A, Martí- Soler H, Soriano A, Hurtado JC, Subirà C, et al. (2020) Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE 15(11): e0242184. https://doi.org/10.1371/ journal.pone.0242184
Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020. http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989.Accessed 2nd May 2020
Amit N. Patel , Sapan S. Desai, David W. Grainger, Mandeep R. Mehra. Usefulness of Ivermectin in COVID-19 Illness - SSRN-id3580524.pdf. https://papers. ssrn.com/sol3/papers. cfm? abstract_ id=3580524 Accessed 28th April 2020
Andrew Hill, Anna Garratt, Jacob Levi, Jonathan Falconer, Leah Ellis, Kaitlyn McCann, Victoria Pilkington, Ambar Qavi, Junzheng Wang, Hannah Wentzel, Metaanalysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection, Open Forum Infectious Diseases, Volume 8, Issue 11, November 2021, ofab358, https://doi.org/10.1093/ofid/ofab358
Ivermectin treatment for COVID-19: Realtime meta- analysis of 4 studies. https://ivmmeta.com/ (2021)
Andrew Bryant, Theresa A. Lawrie, Therese Dowswell, Edmund J. Fordham, Scott Mitchell, Sarah R. Hill, Tony C. Tham Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines Am J Ther. 2021 JulAug; 28(4): e434–e460. Published online 2021 Jun 21. doi: 10.1097/ MJT.0000000000001402
Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020; 40:37. Published 2020 Oct 1. doi:10. 1186/s41232-020-00146-3
Alam, M. T., Murshed, R., Gomes, P. F., Masud, Z. M., Saber, S., Chaklader, M. A., Khanam, F., Hossain, M., Momen, A. B. I. M., Yasmin, N., Alam, R. F., Sultana, A., & Robin, R. C. (2020). Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a
Selected Tertiary Hospital in Dhaka – An Observational Study. European Journal of Medical and Health Sciences, 2(6). https://doi.org/10.24018/ejmed. 2020. 2.6.599
Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents. 2021;57(1):106248. doi:10.1016/ j.ijantimicag.2020.106248.
Behera P, Patro BK, Singh AK, Chandanshive PD, S. R. R, Pradhan SK, et al. (2021) Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS ONE 16(2): e0247163. https://doi.org/ 10.1371/journal.pone.0247163
Kory, Pierre MD1,*; Meduri, Gianfranco Umberto MD2 ; Varon, Joseph MD3; Iglesias, Jose DO4 ; Marik, Paul E. MD5
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics: May/June 2021 - Volume 28 - Issue 3 - p e299-e318 doi: 10.1097/ MJT.0000000000001377
UCL News. Vaccine antibody levels start to wane at around 2-3 months. 22 July 2021. https://www.ucl.ac.uk/news/ 2021/jul/vaccine-antibody-levels-startwane-around-2-3-months.
